Himedia Laboratories Pvt Ltd.

CHICAGO, Aug. 7, 2023 /PRNewswire/ -- In the near future, the blood culture tests industry is poised for remarkable advancements driven by cutting-edge technologies and innovative research. With a growing emphasis on personalized medicine and rapid diagnostic solutions, blood culture tests will witness a transformative shift towards faster, more accurate, and comprehensive detection of infectious agents. Microfluidic-based platforms will become increasingly prevalent, enabling higher-throughput analysis and reduced turnaround times, crucial for early detection and effective treatment of infections. Additionally, advancements in machine learning algorithms and artificial intelligence will facilitate the real-time analysis of vast datasets, improving pathogen identification and antibiotic resistance profiling. Furthermore, the integration of point-of-care blood culture devices with telemedicine and cloud-based platforms will enhance accessibility and facilitate seamless communication between healthcare providers and patients. As the industry continues to thrive, these advancements will play a pivotal role in revolutionizing infectious disease diagnosis and treatment, ultimately leading to improved patient outcomes and global healthcare systems. Blood Culture Tests Market in terms of revenue was estimated to be worth $5.2 billion in 2023 and is poised to reach $7.6 billion by 2028, growing at a CAGR of 8.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in this market is primarily fueled by growing demand for rapid diagnostic techniques, high prevalence of infectious diseases, growing incidence of sepsis cases and high-cost treatment, rising geriatric population and high incidence of bloodstream infections. Alternatively, lack of trained laboratory technicians and high cost of automated instruments are expected to restrain the market growth in the upcoming years. Download an Illustrative overview: Browse in-depth TOC on "Blood Culture Tests Market" 269 - Tables 43 - Figures 276 - Pages Blood Culture Tests Market Scope: The Automated Blood Culture Tests segment is expected to grow the highest during the forecast period Based on method, conventional/manual blood culture and automated blood culture methods are the different blood culture tests market segments. The automated blood culture segment is expected to grow the highest during the forecast period. The quick turnaround time and reduced risk of contamination due to low manual intervention drives the growth of the automated blood culture method segment in the blood culture tests market. The Consumables segment is expected to grow the highest during the forecast period Based on product, the consumables, instruments, and software and services, make up the major market segments for blood culture tests market. The consumables segment not only has the largest share but is also expected to grow the highest during the forecast period. The large share of this segment is attributed to the repeated purchase of media for the detection of bacteria, fungi, and yeast and increase in drug-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing bacteria. The Molecular Technologies segment is to witness the highest growth during the forecast period Based on technology, the blood culture tests market is categorized into distinct segments, including molecular technologies, proteomics and culture-based technologies. Among these, molecular technologies segment is to witness the highest growth during the forecast period. This can be attributed to several factors, such as the increasing incidence of sepsis, which demands rapid diagnostic techniques for detecting the presence of fungi, bacteria, and mycobacteria from blood samples. The Bacteremia segment is expected to look for the highest growth during the forecast period Based on application, the market for blood culture tests is divided into fungemia, mycobacterial detection and bacteremia. Bacteremia segment is expected to look for the highest growth in the blood culture tests market. The highest growth of this segment is primarily attributed to the increasing number of bloodstream infections and the growing number of sepsis cases worldwide. The Hospital Laboratories segment has accounted for the largest share during the forecast period Based on end users, the bloodculture tests market is bifurcated into reference laboratories,hospital laboratories, academic research laboratories, and other laboratories (includes physician office laboratories (POLS), pathology laboratories, independent research laboratories and bacteriological laboratories). The hospital laboratories segment has accounted for the largest share in this market. This is due to the rising number of sepsis cases in emergency departments (EDs), as sepsis is most commonly observed in EDs. Asia-Pacific is to witness the highest growth during the forecast period. The Asia-pacific blood culture tests market is expected to grow at the highest CAGR during the forecast period of 2023-2028. The high growth rate of this market can be attributed to the high prevalence of sepsis and government initiatives to increase its awareness, increasing demand for effective diagnostic techniques, and growing regulatory approvals and availability of blood culture test products in the region. Request Sample Pages: Blood Culture Tests Market Dynamics: Drivers: Growing incidence of sepsis cases and high cost of treatment Restraints: Lack of trained laboratory technicians Opportunities: Growth opportunities in emerging economies Challenges: Market Cannibalization for conventional products Key Market Players: The major players in this market are Biosystems, Inc (US), BINDER GmBH (Germany), Biobase Biotech (Jinan) Co., Ltd. (China), Scenker Biological Technology Co., Ltd. (China), Bulldog Bio (England), Anaerobe Systems, Inc. (US), Himedia Laboratories Pvt. Ltd. (India), Autobio Diagnostics Co., Ltd. (China), Axiom Laboratories (India), Mikroscan Technologies, Inc. (US), Labotronics Ltd. (UK), Hardy Diagnostics (US), OpGen, Inc. (US), Meditech Technologies India Private Limited (India), Iridica (US), Thermo Fisher Scientific (US), Danaher (US), Luminex Corporation (US), Bruker (US), Roche Diagnostics (Switzerland), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Terumo Corporation (Japan), Becton, Dickinson and Company (US) and BioMérieux (France). Recent Developments: In 2023, BioMérieux, announced that it has submitted a 510(k) premarket notification to the US Food and Drug Administration (FDA) for the VITEK REVEAL, formerly known as SPECIFIC REVEALRapid AST System. This rapid, modular, antimicrobial-susceptibility test platform that can deliver actionable results for Gram-negative bacteria directly from positive blood cultures in an average of five and a half hours1 enabling same-day treatment decision-making for patients suffering from bacteremia sepsis. In 2023, Bruker introduces fast next-generation MALDI Biotyper IVD Software. The MBT Compass HT IVD software provides a high sample throughput for microbial identification with time-to-result of ~5 minutes for 96 sample spots. Because of a fast sample target exchange, the MBT system can now analyze up to 600 samples per hour, while covering over 4,600 species in the reference library. In 2022, BioMérieux, a world leader in the field of in vitro diagnostics, has entered into an agreement to acquire Specific Diagnostics, a privately held US based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures. BioMérieux has held a minority stake in Specific Diagnostics since 2019, and the two companies had signed a co-distribution agreement covering the European market in 2021. With the addition of SPECIFIC REVEAL Rapid AST, the unique and comprehensive BioMérieux Sepsis Solution allows same-day AST results for Gram-negative bacteria to enable more targeted therapy and improve patient outcomes. In 2022, Beckman Coulter, partnered with Germany-based company Smart4Diagnostics to close the preanalytical data gap between blood collection and laboratory analysis due to errors that take place before the sample arrives in the laboratory, such as sample collection, patient identification, sample handling, sample transportation, sample loss, etc. In 2020, Becton, Dickinson and Company obtained the CE mark approval for the BD Vacutainer UltraTouch Push Button Blood Collection Set (BCS) with Preattached Holder. The one-handed safety activation of the push button allows clinicians to activate the safety mechanism while still attending to the patient and venipuncture site. Get 10% Free Customization on this Report: Blood Culture Tests Market Advantages: Early Detection of Infections: Blood culture tests are highly sensitive and can detect a wide range of bacterial, fungal, and viral infections in the bloodstream, even before symptoms become apparent. Early detection allows for prompt initiation of appropriate treatment, improving patient outcomes and reducing the risk of complications. Guiding Targeted Antibiotic Therapy: Identifying the specific pathogen causing the infection enables healthcare providers to prescribe targeted antibiotic therapy. This approach minimizes the unnecessary use of broad-spectrum antibiotics, reducing the risk of antibiotic resistance and preserving the effectiveness of antibiotics for future use. Monitoring Treatment Effectiveness: Blood culture tests enable healthcare professionals to monitor the effectiveness of antibiotic treatment over time. Serial blood cultures can show a decline in pathogen levels, indicating successful therapy, or the emergence of antibiotic resistance, prompting adjustments to the treatment plan. Infection Control in Healthcare Settings: Blood culture tests play a vital role in identifying outbreaks of infectious diseases in healthcare facilities. Timely detection and appropriate infection control measures help prevent the spread of infections among patients and healthcare workers. Impact on Public Health: Blood culture tests contribute valuable data to public health surveillance systems, aiding in the identification and tracking of emerging infectious diseases. This information assists health authorities in implementing targeted interventions and preventive measures at a broader level. Personalized Medicine: With advancements in technology, blood culture tests are becoming more accessible and adaptable to individual patient needs. This fosters the concept of personalized medicine, tailoring treatment plans based on the specific pathogens and their drug resistance profiles found in a patient's bloodstream. Non-Invasive Alternatives: In some cases, blood culture tests can replace more invasive diagnostic procedures, such as tissue biopsies or lumbar punctures, reducing patient discomfort and potential complications. Research and Development: Blood culture test data fuels ongoing research and development efforts, leading to the creation of improved diagnostic tools, new antimicrobial agents, and enhanced treatment strategies. In conclusion, the blood culture tests market's advantages lie in its ability to offer early and accurate detection of infections, guide targeted therapies, contribute to infection control and public health efforts, foster personalized medicine, and support medical research and development. These benefits collectively contribute to better patient care, improved public health outcomes, and the advancement of medical knowledge in the field of infectious diseases. Related Reports: Blood Collection Devices Market - Global Forecasts to 2027 Sepsis Diagnostics Market - Global Forecasts to 2026 Blood Screening Market - Global Forecasts to 2026 Clinical Microbiology Market - Global Forecasts to 2025 Patient Blood Management Market - Global Forecasts to 2024 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: Visit Our Website: Content Source: Logo: SOURCE MarketsandMarkets

DUBLIN, Oct. 21, 2022 /PRNewswire/ -- The "Global Serum-Free Media Market: Focus on Media Type, End User, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering. The global market for serum-free media was valued at $1,022.4 million in 2021 and is expected to reach $3,920.5 million by 2032, registering a CAGR of 12.73% during the forecast period 2022-2032. The growth in the global serum-free media market is expected to be driven by factors such as the low risk of contamination in the media, rising awareness of media-based diagnostic testing, and significant number of funding for executing research and development. Market Lifecycle Stage The global serum-free media market is progressing rapidly with a significant increase in research and development activities pertaining to a wide range of animal component-free products for disease detection, accentuating their criticality in healthcare. Serum-free media has a critical role in the cellular diagnostics approach, as it ensures the safe and effective application for improved cell culture and cell therapy-based methods. Increasing investments in R&D for cell-based diagnostics is one of the major opportunities in the serum-free media market. Several clinical organizations and biopharmaceutical companies are working collaboratively on molecular biology applications, cell biology, cancer research, metagenomics, and plant research using serum-free media as a therapeutic means for applications in several disease indications in order to enable efficient diagnosis, treatment selection, dosage selection, and treatment monitoring. Impact Several techniques are employed in the development of serum-free media utilization for the process of removing cells, tissues, or organs from an animal or plant and putting them into a setting that will help them survive and/or proliferate. The selection of an adequate growth medium for in vitro cultivation is the most significant and important phase in cell culture. A growth medium, also known as a culture media, is a solution, gel, or powder that promotes the development of cells, small plants, or microorganisms. This serum-free medium market space has been segmented into different media types that include common serum-free, xeno-free, chemically-defined, animal component-free, and protein-free. Some of these media types are described in brief as follows: Common serum-free media: In common serum-free media, the composition is precisely defined, ensuring lot-to-lot consistency and eliminating the need to screen new lots of serum. In addition to facilitating the growth of numerous cell types for study, serum-free media also provide the advantage of removing the threat of infectious pathogens. The common serum-free media does not include human or animal serum or plasma in its direct or basic constituents. Chemically-defined media: Chemically-defined media is beneficial for a range of physiological research as well as for examining the minimal needs of microorganisms. Chemically-defined media are known to increase productivity and reduce costs in cell culture applications. A specified medium will enhance reproducibility and enable a more precise prediction of the final yield from a certain procedure. Animal component-free media: Animal-free media, also known as animal component-free and animal origin-free cell culture media, can offer the essential components required for cell growth and performance similar to the media, including serum, but without the drawbacks associated with using the serum. Animal component-free media not only mitigates the risk of prions and other viral contaminants but also improves regulatory approvals and speed-to-market. Protein-free media: The protein-free media are ideal for producing proteins as they promote healthy cell development and excellent protein yield. The proteins in the protein-free medium can be substituted with low-molecular-weight components such as peptides, hormones, and inorganic ions. However, protein-free designated commercially available media frequently contain just trace amounts of recombinant proteins. Impact of COVID-19 The current global serum-free media market comprises different media types. The unexpected crisis of the pandemic has surged the demand for essentials and thus, increased the demand for serum-free media. There was increased demand for serum-free media from biopharmaceutical companies. Overall, the impact of COVID-19 on the global serum-free media market size has been low-moderate. Some of the market players have reported a slight decline in sales. However, it is worth mentioning that with the ease of restrictions after Q2 2021, the market for serum-free media gained significant momentum and is anticipated to grow during the forecast period 2022-2032. As a result of the pandemic and reduced output at manufacturing facilities, the pandemic caused a short-term drop in manufacturing and sales of serum-free media. The global serum-free media market will eventually return to its usual growth trajectory over time. With many people impacted by COVID-19 all around the world, pharmaceutical companies are ramping up manufacturing to create vaccinations. Such trends are generating revenue potential for serum-free media market participants. Lonza Group AG, a Swiss multinational chemicals and biotechnology firm, is earning notoriety for its non-animal ProVeroTM1 Serum-free Medium, which aids in vaccine manufacture. Recent Developments in the Global Serum-Free Media Market In August 2022, Thermo Fisher Scientific Inc. expanded the cell culture media manufacturing facility in Grand Island, New York, to support the production of new vaccines and biologics. This expansion would support the worldwide media supply and increase the capacity to create high-quality technologies. In May 2022, FUJIFILM Irvine Scientific completed its new bioprocessing innovation and collaboration center in China. The new center would enable local resources and expertise required to optimize cell culture media and workflows to aid the production of vaccines, advanced therapies, and biotherapeutic drug development in China. In September 2021, Bio-Techne Corporation developed a new medium ExCellerate IpsC expansion medium, for IpsC research in regenerative medicine. In April 2021, PromoCell GmbH launched an upgrade to its Keratinocyte Cell Culture Portfolio. The company expanded its improved animal-extract-free Keratinocyte Growth Medium 3 for the standardized isolation and development of juvenile and adult Normal Human Keratinocytes. In March 2021, the company also launched its improved third-generation Melanocyte Cell Culture Portfolio. Melanocyte Growth Medium M3 is a serum-free, bovine pituitary extract (BPE)-free, and phorbol myristate acetate (PMA)-free media formulation. Demand - Drivers and Limitations Following are the demand drivers for the global serum-free media market: Low Risk of Contamination as a Demand Driver Launch of innovative products in Serum-Free Media Ecosystem Low reception cost involving small and medium enterprises in comparison to animal derived media The market is expected to face some limitations too due to the following challenges: Slow Growth Rate in Comparison to Serum-Supplemented Media Requirement of Diverse Cell-Type for Specific Media Formulation Key Market Players and Competition Synopsis The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration. Some of the prominent names established in this market are: Company Type 1: Serum-Free Media Private Industry MP BIOMEDICALS. HiMedia Laboratories R&D Systems, Inc. Sino Biological, Inc. PAN-Biotech. PromoCell GmbH Athena Environmental Sciences, Inc. STEMCELL Technologies Inc. Company Type 2: Serum-Free Media Public Industry Corning Incorporated Lonza Group AG Merck KgaA Sartorius AG Thermo Fisher Scientific Inc. FUJIFILM Holdings Corporation Danaher. Key Topics Covered: 1 Market Overview 2 Global Serum-Free Media: Market Dynamics 2.1 Overview 2.2 Impact Analysis 2.2.1 Drivers 2.2.1.1 Low Risk of Contamination as a Demand Driver 2.2.1.2 Launch of innovative products in Serum-Free Media Ecosystem 2.2.1.3 Low reception cost involving small and medium enterprises in comparison to animal derived media 2.2.2 Restraints 2.2.2.1 Slow Growth Rate in Comparison to Serum-Supplemented Media 2.2.2.2 Requirement of Diverse Cell-Type for Specific Media Formulation 2.2.3 Opportunities 2.2.3.1 Regulatory Bodies Across the Globe Encourage the Use of Animal-Free Media in Biological Products 2.2.3.2 Extensive Adoption of Serum-Free Media in Biopharmaceutical Companies 3 Global Serum-Free Media (by Media Type), $Mn, 2021-2032 3.1 Overview 3.2 Common Serum-Free 3.3 Xeno-Free 3.4 Chemically-Defined 3.5 Animal Component-Free 3.6 Protein-Free 4 Global Serum-Free Media (by End User), $Million, 2021-2032 4.1 Overview 4.2 Biopharmaceutical Companies 4.2.1 Biopharmaceutical Companies, by Media Type 4.3 Academic and Research Organizations 4.3.1 Academic and Research Organizations, by Media Type 4.4 Clinical Research Organizations 4.4.1 Clinical Research Organizations, by Media Type 4.5 Others 4.5.1 Others, by Media Type 5 Global Serum-Free Media Market (by Region), $Million, 2021-2032 6 Competitive Landscape 6.1 Overview 6.2 Key Developments and Strategies 6.2.1 Business Expansions 6.2.2 Product Launches and Developments 6.2.3 Mergers and Acquisitions 6.2.4 Others 6.3 Market Share Analysis (by Company) 6.4 Growth-Share Analysis (by Company) 7 Company Profiles For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

DUBLIN, Sept. 6, 2022 /PRNewswire/ -- The "Global Recombinant Cell Culture Supplements Market: Focus on Pricing Analysis, Product, Application, Expression System, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering. The global recombinant cell culture supplements market was estimated at $308.6 million in 2021 and is expected to reach $1,188.6 million by 2032, growing at a CAGR value of 12.24% during the forecast period 2022-2032. The growth in the global recombinant cell culture supplements market is expected to be driven by the rising demand for cell culture supplements, increasing investment in life sciences research and development, as well as growing advantages of recombinant supplements over traditional animal-derived supplements. Market Lifecycle Stage The global recombinant cell culture market is increasing at a rapid pace. The growing need for animal-free supplements in cell culture applications is aiding the growth of the recombinant cell culture supplements market. Recombinant cell culture supplements play a crucial role in enhancing cell viability, maintaining a healthy culture, and customizing the cell culture in accordance with the needs of the individual. Increasing demand for immunotherapy and stem cell and regenerative medicine research is one of the major opportunities in the recombinant cell culture supplements market. Several cell culture companies, and biopharmaceutical companies are working collaboratively on drug development and using recombinant cell culture supplements as a therapeutic means for applications in biological drugs. Furthermore, the market witnessed major mergers and acquisitions in the past four years. For instance, recently, in March 2022, Thermo Fisher Scientific Inc. acquired PeproTech, Inc., a company that specializes in the development and manufacturing of recombinant proteins, in a deal of $1.85 billion. Impact Many biopharmaceutical products are being developed by utilizing the cell culture technique. The study of cell physiology and biochemistry is made possible through laboratory cell culture, which also opens up research avenues that are challenging to pursue in vivo. Controlling variables such as the culture media, culture conditions, population density, and growth rate makes it simple to assess the effects of medications or other substances on cultured cells. Additionally, it allows analyzing the function of various genes and offers enormous potential in the field of genetics. It enables the assessment of harmful and carcinogenic chemicals on cells in the fields of oncology and virology and the comprehension of how different medications, viruses, and physical or chemical carcinogens interact. Furthermore, the recombinant cell culture has various applications, such as research on vaccines, stem cells, gene therapy, and genetic engineering, as well as the creation of protein therapies manufacturing of genetically edited proteins such as monoclonal antibodies, insulin, and hormones. Market Dynamics Market Drivers Increasing Demand for Recombinant Cell Culture Supplements Due to their Advantages Increased Funding and Investment in Research and Development for Biopharmaceutical Products in Life Sciences Sector Growing Number of Mergers and Acquisitions for Expanding Recombinant Cell Culture Supplements Portfolio Push from Regulatory Bodies to Utilize Animal-Free Media Supplements in Cell Culture Process Market Restraints Challenging Manufacturing Process of Recombinant Proteins Technical Complexities Associated with Recombinant Cell Culture Supplements Market Opportunities Increasing Need for Immunotherapies and Stem Cell and Regenerative Medicines Increasing Preference for Serum-Free Media Market Segmentation by Product Recombinant Albumin (rAlbumin) Recombinant Insulin (rInsulin) Recombinant Epidermal Growth Factor (rEGF) Recombinant Interleukin Growth Factor (rILGF) Recombinant Transferrin (rTransferrin) Recombinant Trypsin (rTrypsin) Recombinant Insulin-like Growth Factor (rIGF) Recombinant Stem Cell Factor (rSCF) Recombinant Aprotinin (rAprotinin) Recombinant Lysozyme (rLysozyme) Others by Application Stem Cell and Regenerative Medicine Bio-Production Academic and Research Application by Expression System Mammalian E. Coli Yeast Others by Region North America Europe Asia-Pacific Latin America Rest-of-the-World Demand - Drivers and Limitations Following are the demand drivers for the global recombinant cell culture supplements market: Increasing Demand for Recombinant Cell Culture Supplements Due to their Advantages Increased Funding and Investment in Research and Development for Biopharmaceutical Products in Life Sciences Sector Growing Number of Mergers and Acquisitions for Expanding Recombinant Cell Culture Supplements Portfolio Push from Regulatory Bodies to Utilize Animal-Free Media Supplements in Cell Culture Process The market is expected to face some limitations too due to the following challenges: Challenging Manufacturing Process of Recombinant Proteins Technical Complexities Associated with Recombinant Cell Culture Supplements Key Topics Covered: 1 Market Overview 2 Product, $ Mn, 2021-2032 3 Application, $Mn, 2021-2032 4 Expression System, $Mn, 2021-2032 5 Region, $Mn, 2021-2032 6 Competitive Landscape 7 Company Profiles Companies Mentioned Abcam plc. BBI Solutions Corning Incorporated FUJIFILM Irvine Scientific, Inc. Gemini Bioproducts, LLC HiMedia Laboratories InVitria Kingfisher Biotech, Inc. Lonza Group AG Merck KGaA Novus Biologicals, LLC R&D Systems, Inc. Sartorius AG Sino Biological Inc. STEMCELL Technologies Inc. Thermo Fisher Scientific Inc. For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets